Trigen Completes Eur 26.5 Million Financing Round
October 11, 2005 05:12 ET
|
Trigen
MUNICH, Germany and LONDON, Oct. 11, 2005 (PRIMEZONE) -- Trigen Holdings AG, the cardiovascular drug discovery and development company, today announced the completion of a 26.5m euro (US$31.9m)...
Trigen Announces the Successful Completion of a Phase II Study of TGN 255 for Anticoagulation in Haemodialysis
August 09, 2005 19:22 ET
|
Trigen
MUNICH and LONDON, Aug. 9, 2005 (PRIMEZONE) -- Trigen Holdings AG today announced the preliminary results of its Phase II study of anticoagulation in haemodialysis for its novel intravenous...
Trigen and ProCorde Merge to Create Europe's First Broad-based Cardiovascular Biotech Company
April 11, 2005 02:09 ET
|
Trigen
-- Complete pipeline of novel, competitive, clinical-stage products
addressing major in-hospital and out-patient thrombosis markets
-- Extensive portfolio of pre-clinical and discovery-stage
...
Trigen and Eurand announce a development collaboration for Trigen's novel oral anticoagulant, TGN 167
November 23, 2004 02:08 ET
|
Trigen
LONDON and MILAN, Nov. 23, 2004 (PRIMEZONE) -- Trigen Ltd and Eurand today announced a collaboration to develop controlled-release formulations of Trigen's highly-selective, novel oral anticoagulant,...
Trigen's Novel Oral Anti-Coagulant, TGN 167, Successfully Completes Phase I Study
December 16, 2003 02:16 ET
|
Trigen
LONDON, Dec. 16, 2003 (PRIMEZONE) -- Trigen Ltd today announced the successful completion of a Phase I dose escalation study for its highly selective oral direct thrombin inhibitor (DTI), TGN 167,...
Trigen Presents Data on a Neutralising Agent for its Anti-Coagulant Direct Thrombin Inhibitors
December 09, 2003 02:08 ET
|
Trigen
LONDON, Dec. 09, 2003 (PRIMEZONE) -- Trigen Ltd today announced that preclinical studies with a neutralising agent showed a specific, rapid and complete reversal of the anti-coagulant properties of...
Trigen's i.v. Anticoagulant, TGN 255, Successfully Completes Phase I PK/PD Study
December 03, 2003 02:09 ET
|
Trigen
LONDON, U.K., Dec. 03, 2003 (PRIMEZONE) -- Trigen Ltd today announced the successful completion of a Phase I dose escalation study for its intravenous direct thrombin inhibitor, TGN 255, which is...
Trigen Advances Next Generation Anti-Coagulant, Direct Thrombin Inhibitors
November 18, 2003 02:18 ET
|
Trigen
LONDON, Nov. 18, 2003 (PRIMEZONE) -- Trigen Ltd today announced that it has successfully identified two novel, competitive clinical candidates from its Direct Thrombin Inhibitor (DTI) programme,...
Trigen Completes Management Team
August 01, 2002 04:25 ET
|
Trigen
LONDON, August 1, 2002 (PRIMEZONE) -- Trigen Ltd. today announced the appointment of Dr. Suresh Chahwala as VP Drug Discovery and Dr. Sophie Combe as VP Clinical Development. Both appointments bring...
Trigen Expands Executive Management Team
May 09, 2002 03:15 ET
|
Trigen
LONDON, May 9, 2002 (PRIMEZONE) -- Trigen Ltd. today announced the appointment of Tony Kennedy as VP Development and Oliver Boucher as VP Commercial Development.
"We are delighted that Tony and...